Vivos Therapeutics(VVOS)
$0.08-0.00 (-3.80%)
VVOS
Vivos Therapeutics financials statements
$0.08
At close:-0.00 (-3.80%)
Want to see VVOS full AI Analyst Report?
Vivos Therapeutics (VVOS) Ratios
247 Followers
Vivos Therapeutics Ratios
VVOS's free cash flow for Q2 2026 was $-3.13M. For the 2026 fiscal year, VVOS's free cash flow was increased by $18.00K and operating cash flow was $-3.15M. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Mar 25 | Dec 23 | Dec 22 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.24 | 1.50 | 0.34 | 0.80 | 3.64 |
| Quick Ratio | 0.24 | 1.50 | 0.34 | 0.80 | 3.64 |
| Cash Ratio | 0.11 | 1.26 | 0.23 | 0.52 | 3.20 |
| Solvency Ratio | -0.75 | -1.44 | -1.26 | -2.60 | -2.40 |
| Operating Cash Flow Ratio | -0.84 | -2.55 | -1.64 | -2.87 | -2.10 |
| Short-Term Operating Cash Flow Coverage | -1.83 | 0.00 | -25.20 | -46.75 | -12.44 |
| Net Current Asset Value | $ -22.32M | $ 143.00K | $ -7.86M | $ -3.50M | $ 19.17M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.54 | 0.10 | 0.19 | 0.18 | 0.05 |
| Debt-to-Equity Ratio | -9.06 | 0.19 | 4.85 | 0.50 | 0.06 |
| Debt-to-Capital Ratio | 1.12 | 0.16 | 0.83 | 0.33 | 0.06 |
| Long-Term Debt-to-Capital Ratio | -0.46 | 0.00 | 0.00 | 0.00 | 0.01 |
| Financial Leverage Ratio | -16.88 | 1.92 | 26.11 | 2.86 | 1.32 |
| Debt Service Coverage Ratio | -2.38 | 0.00 | -35.18 | -58.14 | -15.28 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -1390.79 |
| Debt to Market Cap | 0.42 | 0.00 | 0.03 | 0.05 | 0.03 |
| Interest Debt Per Share | 1.31 | 0.30 | 1.64 | 2.62 | 1.94 |
| Net Debt to EBITDA | -0.58 | 0.45 | -0.02 | 0.05 | 1.15 |
| Profitability Margins | |||||
| Gross Profit Margin | 60.44% | 60.00% | 59.93% | 62.52% | 74.65% |
| EBIT Margin | -121.71% | -74.09% | -125.32% | -156.21% | -120.07% |
| EBITDA Margin | -114.21% | -70.22% | -120.82% | -152.03% | -115.73% |
| Operating Profit Margin | -114.05% | -74.32% | -125.32% | -156.21% | -115.32% |
| Pretax Profit Margin | -121.71% | -74.09% | -98.42% | -148.81% | -120.15% |
| Net Profit Margin | -121.71% | -74.09% | -98.42% | -148.81% | -120.18% |
| Continuous Operations Profit Margin | -121.71% | -74.09% | -98.42% | -148.81% | -120.15% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.02% |
| EBT Per EBIT | 106.72% | 99.69% | 78.53% | 95.26% | 104.20% |
| Return on Assets (ROA) | -84.41% | -72.86% | -126.59% | -173.80% | -60.24% |
| Return on Equity (ROE) | 1424.83% | -140.01% | -3304.87% | -496.67% | -79.46% |
| Return on Capital Employed (ROCE) | -281.15% | -108.39% | -502.64% | -362.40% | -74.37% |
| Return on Invested Capital (ROIC) | -123.14% | -103.60% | -394.08% | -323.19% | -70.77% |
| Return on Tangible Assets | -169.37% | -92.25% | -181.91% | -225.48% | -66.52% |
| Earnings Yield | -101.79% | -51.71% | -89.54% | -257.76% | -42.48% |
| Efficiency Ratios | |||||
| Receivables Turnover | 11.03 | 34.96 | 68.32 | 35.06 | 9.82 |
| Payables Turnover | 4.11 | 5.48 | 2.58 | 4.26 | 4.65 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 2.20 | 3.43 | 2.94 | 3.35 | 5.98 |
| Asset Turnover | 0.69 | 0.98 | 1.29 | 1.17 | 0.50 |
| Working Capital Turnover Ratio | -3.12 | -12.89 | -4.44 | 1.74 | 1.04 |
| Cash Conversion Cycle | -55.72 | -56.22 | -136.24 | -75.35 | -41.28 |
| Days of Sales Outstanding | 33.08 | 10.44 | 5.34 | 10.41 | 37.16 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 88.80 | 66.66 | 141.58 | 85.76 | 78.44 |
| Operating Cycle | 33.08 | 10.44 | 5.34 | 10.41 | 37.16 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.49 | -2.53 | -9.80 | -21.28 | -18.53 |
| Free Cash Flow Per Share | -1.71 | -2.64 | -10.46 | -22.28 | -21.35 |
| Dividend Paid and CapEx Coverage Ratio | -6.52 | -22.34 | -14.88 | -21.20 | -6.57 |
| Capital Expenditure Coverage Ratio | -6.52 | -22.34 | -14.88 | -21.20 | -6.57 |
| Operating Cash Flow Coverage Ratio | -1.13 | -8.39 | -5.99 | -8.12 | -9.64 |
| Operating Cash Flow to Sales Ratio | -0.88 | -0.84 | -0.87 | -1.22 | -0.93 |
| Free Cash Flow Yield | -84.41% | -61.57% | -84.05% | -221.72% | -37.95% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.99 | -1.93 | -1.12 | -0.39 | -2.35 |
| Price-to-Sales (P/S) Ratio | 1.20 | 1.43 | 1.10 | 0.58 | 2.83 |
| Price-to-Book (P/B) Ratio | -14.00 | 2.71 | 36.91 | 1.93 | 1.87 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -1.18 | -1.62 | -1.19 | -0.45 | -2.63 |
| Price-to-Operating Cash Flow Ratio | -1.37 | -1.70 | -1.27 | -0.47 | -3.04 |
| Price-to-Earnings Growth (PEG) Ratio | 0.14 | 0.02 | 0.02 | -0.05 | 0.72 |
| Enterprise Value Multiple | -1.62 | -1.59 | -0.93 | -0.33 | -1.30 |
| Enterprise Value | 32.33M | 16.79M | 15.52M | 8.14M | 25.38M |
| EV to EBITDA | -1.62 | -1.59 | -0.93 | -0.33 | -1.30 |
| EV to Sales | 1.85 | 1.12 | 1.12 | 0.51 | 1.50 |
| EV to Free Cash Flow | -1.84 | -1.27 | -1.22 | -0.40 | -1.40 |
| EV to Operating Cash Flow | -2.12 | -1.32 | -1.30 | -0.42 | -1.61 |
| Tangible Book Value Per Share | -1.38 | 0.94 | -2.34 | 1.80 | 26.32 |
| Shareholders’ Equity Per Share | -0.15 | 1.58 | 0.34 | 5.22 | 30.07 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 1.70 | 2.99 | 11.32 | 17.41 | 19.88 |
| Net Income Per Share | -2.07 | -2.22 | -11.14 | -25.90 | -23.89 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 0.79 | 0.95 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 |
| SG&A to Revenue | 1.67 | 1.30 | 1.63 | 1.81 | 1.53 |
| Stock-Based Compensation to Revenue | 0.04 | 0.05 | 0.07 | 0.15 | 0.16 |
| Income Quality | 0.72 | 1.14 | 0.88 | 0.82 | 0.78 |
Currency in USD

